Anixa Biosciences (ANIX) announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical trial evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer. Dr. Amit Kumar, Chairman and CEO of Anixa, stated, “With the completion of the fourth cohort, we are gaining important insights into the potential of our CAR-T therapy for ovarian cancer at higher dose levels. While this study is primarily designed to assess safety, we are encouraged by the early indications of potential efficacy, and look forward to initiating the next dose cohort following the standard safety review.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa receives notice of allowance in China for cancer vaccine technology patent
- Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort
- Anixa Biosciences issued additional U.S. patent for CAR-T technology
- Anixa Biosciences: Promising Developments and Strong Intellectual Property Bolster Buy Rating
- Anixa plans to begin Phase 2 of breast cancer vaccine trial